Primary cutaneous follicle center lymphoma, marginal zone lymphoma, and diffuse large b-cell lymphoma, were 3 subgroups assessed in a 2021 update. Menu SECTIONS News ...

B-cell lymphomas, which tend to be nodal based, are the more common type, and only rarely have cutaneous manifestations. In contrast, however, T-cell lymphomas commonly manifest in the skin.

TOPLINE: In a large US cohort study, patients with primary cutaneous B-cell lymphoma (pCBCL) had significantly higher risks of developing hematologic and prostate cancers.. METHODOLOGY ...

Foss FM, Kim YH, Prince HMM, et al. Efficacy and safety of E7777 (improved purity denlieukin diftitox [ONTAK]) in patients with replased or refractory cutaneous T-cell lymphoma: results from ...

A new study finds that dupilumab is associated with an increased risk for cutaneous T-cell lymphoma in patients taking the drug for atopic dermatitis.“Dupilumab, a human monoclonal antibody ...

The FDA approved the novel immunotherapy denileukin diftitox-cxdl for treatment of certain patients with relapsed or refractory cutaneous T-cell lymphoma.The indication applies to use of the agent ...

Purpose Three classification and prognostic systems exist for primary cutaneous B-cell lymphoma (PCBCL). Whereas the WHO classification defines its categories based on histology, both the European ...